CNS Pharmaceuticals Files S-1/A Amendment
Ticker: CNSP · Form: S-1/A · Filed: May 12, 2025 · CIK: 1729427
| Field | Detail |
|---|---|
| Company | Cns Pharmaceuticals, Inc. (CNSP) |
| Form Type | S-1/A |
| Filed Date | May 12, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, s-1/a, pharmaceuticals, registration
TL;DR
CNS Pharma filed an S-1/A amendment, looks like they're still prepping for a public offering.
AI Summary
CNS Pharmaceuticals, Inc. filed an S-1/A amendment on May 12, 2025, for its registration statement. The company, incorporated in Nevada, is in the pharmaceutical preparations industry and is based in Houston, Texas. This filing is an amendment to a previous registration, indicating ongoing efforts to register securities.
Why It Matters
This filing indicates CNS Pharmaceuticals is actively working through the process of registering securities, which is a necessary step for public offerings or other significant capital-raising activities.
Risk Assessment
Risk Level: medium — S-1/A filings are typically associated with companies seeking to raise capital, which can involve inherent risks for investors depending on the company's stage and the specifics of the offering.
Key Numbers
- 333-286529 — SEC Registration Number (Identifies the specific registration statement being amended.)
- 2834 — SIC Code (Indicates the company operates in the Pharmaceutical Preparations industry.)
Key Players & Entities
- CNS Pharmaceuticals, Inc. (company) — Registrant
- May 12, 2025 (date) — Filing Date
- 333-286529 (registration_number) — SEC Registration Number
- John Climaco (person) — Chief Executive Officer
- Houston, TX (location) — Principal Executive Offices
FAQ
What is the purpose of this S-1/A filing?
This is an amendment (Amendment No. 1) to a Form S-1 registration statement, indicating that CNS Pharmaceuticals, Inc. is making revisions or additions to its initial filing as required by the SEC.
When was this amendment filed?
The amendment was filed with the SEC on May 12, 2025.
Who is the Chief Executive Officer of CNS Pharmaceuticals, Inc.?
Mr. John Climaco is listed as the Chief Executive Officer.
What is the principal business address of the company?
The principal executive offices are located at 2100 West Loop South, Suite 900, Houston, TX 77027.
In which state was CNS Pharmaceuticals, Inc. incorporated?
The company was incorporated in Nevada (NV).
Filing Details
This Form S-1/A (Form S-1/A) was filed with the SEC on May 12, 2025 by John Climaco regarding CNS Pharmaceuticals, Inc. (CNSP).